NUC-7738在早期试验中强化了肾癌和黑瘤癌症的PD-1治疗,显示出抵制治疗阻力的希望。 NUC-7738 boosted PD-1 therapy in kidney and melanoma cancers in early trials, showing promise against treatment resistance.

NuCana在2025年ESBO大会上报告说,NUC-7738与PD-1抑制剂相结合,大大加强了使用病人免疫细胞的肾细胞癌类组织在肾细胞癌细胞中的肿瘤细胞死亡。 NuCana reported at the 2025 ESMO Congress that NUC-7738, when combined with PD-1 inhibitors, significantly enhanced tumor cell killing in renal cell carcinoma organoids using patient-derived immune cells. 根据10个样本得出的临床初步调查结果表明,该药物扰乱了RNA的多联发性并改变了基因表达方式,有可能克服免疫疗法的抗药性。 The preclinical findings, based on ten samples, suggest the drug disrupts RNA polyadenylation and alters gene expression, potentially overcoming immunotherapy resistance. 这些结果与正在进行的第1/2阶段NuTide:701试验的早期临床数据一致。 NUC-7738试验显示PD-1抗抑制性黑素瘤患者的安全状况有利、肿瘤收缩和长期无进展存活。 These results align with early clinical data from the ongoing Phase 1/2 NuTide:701 trial, where NUC-7738 showed a favorable safety profile, tumor shrinkage, and prolonged progression-free survival in PD-1 inhibitor-resistant melanoma patients. 试验范围正在扩大,增加了28名病人,努卡纳计划与美国林业发展局讨论下一步的监管措施。 The trial is expanding to include 28 more patients, and NuCana plans to discuss regulatory next steps with the U.S. FDA. 该公司认为,NUC-7738可以通过针对肿瘤微环境,加强多种癌症的PD-1治疗。 The company believes NUC-7738 may enhance PD-1 therapy across multiple cancers by targeting the tumor microenvironment.